2-bromomethyl-6-fluoronaphthalene | 581-72-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-bromomethyl-6-fluoronaphthalene
• 英文别名: 2-(Bromomethyl)-6-fluoronaphthalene
• CAS: 581-72-6
• 化学式: C₁₁H₈BrF
• 分子量: 239.087
• InChiKey: FQNISYMJARSLPX-UHFFFAOYSA-N

物化性质

• 熔点：
  53 °C
• 沸点：
  125-130 °C(Press: 2 Torr)
• 密度：
  1.520±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromomethyl-6-fluoronaphthalene 在 盐酸羟胺 、 sodium methylate 作用下， 以 甲醇 、 水 、 二甲基亚砜 、 乙腈 为溶剂， 反应 20.5h， 生成
  参考文献：
  名称：

  Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. Substitution at the 1-, 5-, or 8-positions of the naphthalene ring with a halogen was found to be beneficial to antihyperglycemic activity. 4-[(5-Chloronaphthalen-2-yl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide (45), one of the most potent compounds in this series, was selected for further pharmacological evaluation.

  DOI：

  10.1021/jm00069a006
• 作为产物：
  描述：

  对氟苯乙酰氯 在 N-溴代丁二酰亚胺(NBS) 、 三氯化铝 、 三苯基甲醇 、 偶氮二异丁腈 、 四氯化钛 、 三氟乙酸 作用下， 以 四氢呋喃 、 四氯化碳 、 二氯甲烷 为溶剂， 反应 50.75h， 生成 2-bromomethyl-6-fluoronaphthalene
  参考文献：
  名称：

  Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. Substitution at the 1-, 5-, or 8-positions of the naphthalene ring with a halogen was found to be beneficial to antihyperglycemic activity. 4-[(5-Chloronaphthalen-2-yl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide (45), one of the most potent compounds in this series, was selected for further pharmacological evaluation.

  DOI：

  10.1021/jm00069a006

文献信息

• BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF
  申请人：Tempest Therapeutics, Inc.

  公开号：US20190315712A1

  公开（公告）日：2019-10-17

  Compounds, compositions and methods are provided for modulating the activity of EP 2 and EP 4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP 2 and EP 4 receptors. In certain embodiments, the compounds are antagonists of both the EP 2 and EP 4 receptors.

  提供了用于调节EP2和EP4受体活性的化合物、组合物和方法，以及用于治疗、预防和改善与EP2和EP4受体活性相关的疾病或疾病症状的一种或多种方法。在某些实施例中，这些化合物是EP2和EP4受体的拮抗剂。
• d-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold
  作者：Niyada Hin、Bridget Duvall、James F. Berry、Dana V. Ferraris、Rana Rais、Jesse Alt、Camilo Rojas、Barbara S. Slusher、Takashi Tsukamoto

  DOI：10.1016/j.bmcl.2016.02.068

  日期：2016.4

  4-triazin-6(1H)-one derivatives were designed and synthesized as a new class of d-amino acid oxidase (DAAO) inhibitors. Some of the newly synthesized derivatives showed potent inhibitory activity against human DAAO with IC50 values in the nanomolar range. Among them, 6-hydroxy-3-phenethyl-1,2,4-triazin-5(2H)-one 6b and 3-((6-fluoronaphthalen-2-yl)methylthio)-6-hydroxy-1,2,4-triazin-5(2H)-one 6m were found

  设计并合成了一系列3-取代的5-羟基-1,2,4-三嗪-6（1H）-one衍生物，作为一类新型的d-氨基酸氧化酶（DAAO）抑制剂。一些新合成的衍生物显示出对人DAAO的有效抑制活性，IC50值在纳摩尔范围内。其中6-羟基-3-苯乙基-1,2,4-三嗪-5（2H）-一6b和3-（（6-氟萘-2-基）甲硫基）-6-羟基-1,2，发现4-triazin-5（2H）-1 6m在小鼠肝微粒体中代谢稳定。另外，与单独口服d-丝氨酸相比，发现化合物6b可在小鼠中口服获得并且在与d-丝氨酸共同给药后能够增强血浆d-丝氨酸水平。
• Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
  申请人：SmithKline Beecham p.l.c.

  公开号：US06458779B1

  公开（公告）日：2002-10-01

  Compounds of Formula (1) wherein: R is methyl substituted by one to three groups from alkyl, aryl, alkenyl, and alkynyl; n is ) or 1; R1 is arylmethyl or heterocyclylmethyl; R2 is alkyl, alkenyl, cycloalkyl or cycloalkenyl; and R3 is hydrogen, alkyl, alkenyl, alkynyl or aryl; are useful in the treatment of disorders mediated y s-CD23.

  公式（1）中的化合物，其中：R是甲基，被来自烷基、芳基、烯基和炔基的一个到三个基团取代；n为0或1；R1是芳基甲基或杂环烷基甲基；R2是烷基、烯基、环烷基或环烯基；R3是氢、烷基、烯基、炔基或芳基；在治疗通过s-CD23介导的疾病中是有用的。
• [EN] INHIBITORS OF D-AMINO ACID OXIDASE<br/>[FR] INHIBITEURS D'ACIDE AMINÉ D OXYDASE
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2014025993A1

  公开（公告）日：2014-02-13

  D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as therapeutic agents for treating a subject afflicted with one or more cognitive-disorders, such as schizophrenia, including subjects suffering from negative symptoms and cognitive impairments, post-traumatic stress disorder (PTSD), or pain, are disclosed.

  抑制D-氨基酸氧化酶（DAAO）及其使用方法，可以单独使用或与D-丝氨酸或D-丙氨酸结合，以促进NMDA受体介导的神经递质的变构激活，并作为治疗剂用于治疗患有一个或多个认知障碍的受试者，如精神分裂症，包括患有消极症状和认知障碍的受试者，创伤后应激障碍（PTSD）或疼痛等。
• Heterocyclic compounds
  申请人：John Wyeth & Brother, Ltd.

  公开号：US04778802A1

  公开（公告）日：1988-10-18

  The invention relates to compounds of formula ##STR1## or a salt thereof, wherein .dbd.X-- is .dbd.CH-- or .dbd.N--, R and R.sup.1 independently represent hydrogen, halogen or lower alkoxy and R.sup.2 is hydrogen or a substituent selected from halogen, lower alkyl, lower alkoxy or halolower alkyl which compounds exhibit psychotropic activity and are useful as antidepressants.

  该发明涉及公式##STR1##的化合物或其盐，其中.dbd.X--为.dbd.CH--或.dbd.N--，R和R.sup.1独立代表氢、卤素或较低的烷氧基，R.sup.2为氢或从卤素、较低烷基、较低烷氧基或卤代较低烷基中选择的取代基，这些化合物具有精神活性，并可用作抗抑郁剂。